{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T12:03:01Z","timestamp":1766318581664,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Protalix BioTherapeutics"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bcmd.2016.07.002","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T13:07:12Z","timestamp":1468847232000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-na\u00efve patients with Gaucher disease"],"prefix":"10.1016","volume":"78","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorina","family":"Giona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Petakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Terreros Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio Eduardo","family":"Solorio-Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheeba","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sari","family":"Alon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Chertkoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.07.002_bb0005","series-title":"Williams Hematology","first-page":"1121","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Zimran","year":"2016"},{"key":"10.1016\/j.bcmd.2016.07.002_bb0010","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","first-page":"1","article-title":"Gaucher disease: phenotypic and genetic variation","author":"Grabowski","year":"2010"},{"key":"10.1016\/j.bcmd.2016.07.002_bb0015","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2016.07.002_bb0020","first-page":"S6","article-title":"Understanding the natural history of Gaucher disease","volume":"90","author":"Mistry","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.07.002_bb0025","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2016.07.002_bb0030","first-page":"82","article-title":"Management of Gaucher disease: enzyme replacement therapy","volume":"12","author":"Zimran","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.bcmd.2016.07.002_bb0035","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nbt0612-472","article-title":"First plant-made biologic approved","volume":"30","author":"Fox","year":"2012","journal-title":"Nat. Biotechnol."},{"year":"2015","series-title":"Elelyso [Package Insert]","key":"10.1016\/j.bcmd.2016.07.002_bb0040"},{"key":"10.1016\/j.bcmd.2016.07.002_bb0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.bcmd.2016.07.002_bb0050","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","article-title":"Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease","volume":"118","author":"Zimran","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.07.002_bb0055","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ajh.24369","article-title":"Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naive patients with Gaucher disease","volume":"91","author":"Zimran","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.07.002_bb0060","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.24399","article-title":"Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase","volume":"91","author":"Pastores","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.07.002_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2010.10.009","article-title":"Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model","volume":"46","author":"Bracoud","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.07.002_bb0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bcmd.2012.11.001","article-title":"Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease","volume":"50","author":"van Dussen","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.07.002_bb0075","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter","volume":"179","author":"Maas","year":"2002","journal-title":"AJR Am. J. Roentgenol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:55Z","timestamp":1761050095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616300870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":15,"alternative-id":["S1079979616300870"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.07.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-na\u00efve patients with Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}